Theralizumab
TGN1412 (also known as CD28-SuperMAB) is the working name of an anti inflammatory drug which hospitalised 6 volunteers during stage 1 clinical trials in March 2006 [1]. TGN1412 is a humanised monoclonal antibody which acts upon CD28 of the immune system's T cells. It received designation as an orphan medical product from the European Medicine Agency for the treatment of B cell chronic lymphocytic leukemia in March 2005 [2].
The drug was developed by TeGenero and was being tested by Paraxel [3].